Given that the limited number of patients and differences in biologic behavior pose challenges in conducting clinical trials in rare malignancies, researchers determined whether using genomic profiling for rare gynecologic malignancies is feasible and have clinical utility. They analyzed somatic
… Read moreBy Charles Bankhead
No PFS or OS benefit, more toxicity with IP verses IV regimens
Final results of a highly anticipated randomized trial failed to show a survival benefit with intraperitoneal (IP) chemotherapy in patients with newly diagnosed advanced ovarian … Read more
By Anne Trafton
More effective surgery could boost survival rates for ovarian cancer.
Ovarian cancer is usually diagnosed only after it has reached an advanced stage, with many tumors spread throughout the abdomen. Most patients undergo surgery to remove as
Research carried out at the University of Tartu Faculty of Medicine used nanoparticles for the development of new imaging and treatment methods for peritoneal cancers. Tests showed that precision-guided anticancer nanoparticles have improved efficacy and reduced side effects.
One of … Read more
By Beth Fand Incollingo and Kristie L. Kahl
Patients with ovarian cancer tend to underreport their most challenging symptoms; however, an analysis of their online comments could give health care providers insight into how to help.
A machine learning approach … Read more
By Dave Levitan
Niraparib showed promising and clinically relevant activity as therapy for heavily pretreated patients with ovarian cancer, according to a new phase II study. This was particularly true among women with homologous recombination deficiency (HRD)-positive tumors.
“Although most … Read more
By Andrea S. Blevins Primeau, PhD, MBA
There are many different types of agents used in the treatment of cancer, and they can generally be classified according to molecule type or their basic mechanism of action. Different cancer types have … Read more
By Krista Conger
A large study of women with breast and ovarian cancer has revealed significant gaps between national guidelines for genetic testing and actual testing practices, according to researchers from Stanford and five other institutions.
Fewer than a quarter … Read more
By Julia Karow
A study led by researchers at Invitae has found that 23andMe’s direct-to-consumer BRCA test, which tests for three common variants in the BRCA1 and BRCA2 genes and is authorized by the US Food and Drug Administration, misses … Read more
“The longer the history of oral contraceptive use, the greater the protection we observed in terms of reduced chance of dying from aggressive ovarian cancer,” said study first author Jennifer Mongiovi.
The protection that birth control pills offer against ovarian … Read more
By Deborah Abrams Kaplan
Women with this disease are living longer, despite common recurrence.
When Luci Berardi received a stage 4 ovarian cancer diagnosis in October 2010, she did not want to know her chances of survival. The physician told … Read more
IMV Inc., a clinical stage immuno-oncology corporation, today announced preliminary data from the phase 2 cohort of the DECIDE clinical study. Six patients receiving DPX-Survivac monotherapy with intermittent low-dose cyclophosphamide (mCPA) have reached the first CT scan assessment with key … Read more
By Kelly Irvin
Did we bring this scary, painful, financially draining monster into our lives by eating too many cookies and not doing enough jumping jacks? We need a reliable diagnostic screening tool for ovarian cancer and we need it … Read more
My name is Taylor Cochrane, and I am a 35 year old mother, wife, and attorney living in Omaha, NE. On February 2, 2017, I was diagnosed with Small Cell Carcinoma of the Ovary, Hypercalcemic Type (SCCOHT). It is an … Read more
By Christina Bennett, MS
Rucaparib, a poly (ADP-ribose) polymerase (PARP) inhibitor, was effective as a maintenance therapy across all age groups of patients with recurrent ovarian cancer, according to the results of a post-hoc exploratory analysis of ARIEL3 presented at … Read more
By Ian Ingram
Trial stopped for futility, but 13-month OS improvement seen in patients with BRCA mutations.
Trabectedin (Yondelis) plus pegylated liposomal doxorubicin (PLD) failed to improve survival in a phase III trial of third-line ovarian cancer, but a survival … Read more
By Brielle Benyon
Financial distress puts a major burden on patients with cancer and their families. And while there are numerous resources that clinicians can share with their patients to help with co-pays and other money-related issues, they are not … Read more
By Ian Ingram
But showed promise in PD-L1-positive group.
Adding avelumab (Bavencio) to pegylated liposomal doxorubicin (PLD) failed to improve survival outcomes for patients with platinum-resistant or refractory ovarian cancer in a phase III trial reported here.
In the intent-to-treat … Read more
By Christina Bennett, MS
Women at increased risk for hereditary ovarian cancer who underwent risk-reducing salpingo-oophorectomy experienced less worry but worse menopausal symptoms and more regret compared with those who underwent salpingectomy with delayed oophorectomy, the Women Choosing Surgical Prevention … Read more
By Ian Ingram
Clinical benefit rate tops 90% in pair of single-center studies.
Two early trials of novel combinations showed promising clinical activity in gynecologic cancers at a late-breaking abstract session at the Society of Gynecologic Oncology (SGO) meeting here.… Read more
